Ranexa is approved for use in Europe as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. The product is approved for use in 375mg, 500mg and 750mg doses, administered twice daily.
Previously, the company announced that the European Medicines Agency (EMEA) had granted marketing authorization for ranolazine in all 27 EU member states under the brand name Latixa.
Louis Lange, chairman and CEO of CV Therapeutics, said: “Securing approval for the Ranexa brand name in Europe provides important brand synergy in the world’s two largest cardiovascular markets, the US and the EU.”